AI × 生物医药· OpenAI：官网动态（RSS · 排除企业/客户案例）·· 4 hours agoPickScore44
OpenAI Acquires Drug Development Platform Orchestra Bio and Folds It Into Rosalind Life Sciences
In brief
OpenAI announced the acquisition of drug development platform Orchestra Bio, whose team and technology will be integrated into the Rosalind life sciences system. Orchestra's agents help biopharmaceutical teams track R&D progress and analyze the impact of events such as manufacturing batch failures on clinical trial timelines, then propose responses. The piece notes partnerships with Novo Nordisk and Moderna, and that drug development takes 10 to 15 years on average.
Why it matters
OpenAI acquires Orchestra Bio and integrates it into Rosalind for drug development coordination.
Source: AI × 生物医药 · openai.com